Mounjaro side effects: what TikTok gets right and wrong

What did @itsanewmeemj actually say?

The creator opened by listing a string of serious health conditions, including breast cancer, colon cancer, liver cancer, pancreatic cancer, fatty liver disease, gallstones, fertility problems, reduced life expectancy, joint problems, sleep apnea, COPD, diabetes, heart disease, stroke, and raised cholesterol. Then came the reveal: these are risks associated with obesity, not Mounjaro. The point was to flip the script on critics who warn GLP-1 users about long-term medication risks while ignoring what untreated obesity actually does to the body. The creator also claimed tirzepatide has "been around for a long long time" and suggests that losing significant weight directly reduces stroke risk "tomorrow."

The core argument is a rhetorical one: if obesity causes these conditions and Mounjaro helps reduce obesity, critics should weigh the disease burden of excess weight against the risks of the medication itself. That is a legitimate and increasingly mainstream clinical framing. But a few of the supporting details deserve a closer look.

Does the science back this up?

Mostly, yes. The obesity risk list is well-supported. The evidence linking excess adiposity to cardiovascular disease, several cancers, metabolic dysfunction, and respiratory conditions is extensive and replicated across large populations.

The obesity-cancer link is real. A 2016 analysis by Lauby-Secretan et al. in the New England Journal of Medicine identified thirteen cancers with sufficient evidence of association with excess body weight, including colon, liver, and postmenopausal breast cancer. The cardiovascular data is similarly robust: the Framingham Heart Study and decades of follow-up data have consistently linked obesity to elevated stroke and heart disease risk. GLP-1 class drugs, including tirzepatide, have shown meaningful cardiovascular benefits. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) demonstrated that tirzepatide produced significant weight loss, and the SELECT trial for semaglutide (Lincoff et al., 2023, NEJM) showed a 20 percent reduction in major cardiovascular events in people with overweight or obesity and established cardiovascular disease. Tirzepatide's own cardiovascular outcomes trial data is still developing, but early signals are positive.

So the underlying logic, that reducing obesity reduces downstream disease risk, is scientifically sound.

What did they get wrong (or right)?

The creator deserves credit for the main point. Reframing obesity as the documented risk, rather than the medication, is not just rhetorical: it reflects how many endocrinologists and cardiologists now think about GLP-1 therapy. The conditions listed are genuinely associated with obesity, and the science supports that.

Where things get shaky: the claim that Mounjaro has "been around for a long long time" is not accurate. Tirzepatide received FDA approval in May 2022 for type 2 diabetes and in November 2023 for chronic weight management under the Zepbound brand name. It is among the newer agents in this class. Semaglutide has a longer track record, dating to 2017. Long-term safety data beyond five to seven years for any of these agents remains genuinely limited. That is not a reason to avoid them, but it is not nothing either.

The claim that stroke risk is reduced "tomorrow" because of significant weight loss is an overstatement. Cardiovascular risk reduction with weight loss does occur, but it is a gradual process tied to changes in blood pressure, inflammation, and lipid profiles over time, not an overnight shift. The creator's enthusiasm is understandable, but precision matters here.

The "blue tongue" mentioned at the end is likely an unrelated harmless observation, but it is not a known side effect of tirzepatide worth noting clinically.

What should you actually know?

The obesity risk argument is the strongest part of this video and it is worth taking seriously. Critics who focus exclusively on hypothetical long-term medication risks without acknowledging the well-documented, present-tense risks of untreated obesity are applying an asymmetric standard. A 2023 editorial in The Lancet Diabetes and Endocrinology by Rubino et al. made exactly this point: obesity is a chronic disease with serious sequelae, and withholding effective treatment on speculative grounds causes real harm.

That said, GLP-1 receptor agonists including tirzepatide do carry real side effects that deserve honest disclosure. Gastrointestinal effects, nausea, vomiting, and diarrhea, are common especially during dose escalation. There is an FDA black box warning for thyroid C-cell tumors based on rodent studies, though human relevance remains unclear. Pancreatitis, gallbladder disease, and rare cases of gastroparesis have been reported. These are not reasons to dismiss the medication, but anyone using it should be under proper medical supervision, not basing decisions on TikTok content alone.

• Tirzepatide is not a long-standing medication. It was FDA-approved in 2022.
• The obesity-cancer and obesity-cardiovascular disease associations are strongly supported by evidence.
• Weight loss does reduce cardiovascular risk, but not instantaneously.
• Real side effects of tirzepatide exist and should be discussed with a licensed clinician.
• The framing in this video reflects a legitimate shift in how obesity medicine is practiced, even if some specific claims are imprecise.

Bottom line

This video makes a genuinely useful public health point that gets undermined in places by imprecision. The obesity risk list is accurate. The "been around forever" claim about Mounjaro is not. Anyone considering tirzepatide should have a real clinical conversation, not just a TikTok comment section debate.